Dogwood Therapeutics (DWTX) Competitors $4.95 +0.01 (+0.20%) Closing price 08/22/2025 03:57 PM EasternExtended Trading$4.96 +0.01 (+0.30%) As of 08/22/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. XLO, CLNN, MRSN, SCYX, RNXT, ALXO, OKUR, ESLA, CLSD, and BTAIShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Xilio Therapeutics (XLO), Clene (CLNN), Mersana Therapeutics (MRSN), SCYNEXIS (SCYX), RenovoRx (RNXT), ALX Oncology (ALXO), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors Xilio Therapeutics Clene Mersana Therapeutics SCYNEXIS RenovoRx ALX Oncology OnKure Therapeutics Estrella Immunopharma Clearside Biomedical BioXcel Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Which has stronger earnings and valuation, DWTX or XLO? Dogwood Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$12.35M-$18.78-0.26Xilio Therapeutics$6.34M5.75-$58.24M-$0.76-0.93 Does the media prefer DWTX or XLO? In the previous week, Dogwood Therapeutics had 6 more articles in the media than Xilio Therapeutics. MarketBeat recorded 10 mentions for Dogwood Therapeutics and 4 mentions for Xilio Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.09 beat Xilio Therapeutics' score of -0.56 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do institutionals & insiders believe in DWTX or XLO? 9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 3.9% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend DWTX or XLO? Dogwood Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 102.02%. Xilio Therapeutics has a consensus price target of $3.00, indicating a potential upside of 326.68%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk and volatility, DWTX or XLO? Dogwood Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Is DWTX or XLO more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Dogwood Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A N/A -27.41% Xilio Therapeutics -374.79%-399.15%-58.68% SummaryDogwood Therapeutics and Xilio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.46M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-0.2621.0031.3626.05Price / SalesN/A209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book-0.528.129.536.60Net Income-$12.35M-$54.72M$3.26B$265.65M7 Day Performance0.41%2.62%2.14%2.00%1 Month Performance4.65%3.25%3.22%0.46%1 Year PerformanceN/A10.82%30.19%18.88% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics1.7888 of 5 stars$4.95+0.2%$10.00+102.0%N/A$9.46MN/A-0.265News CoverageAnalyst RevisionXLOXilio Therapeutics2.7198 of 5 stars$0.71-0.3%$3.00+324.3%-22.1%$36.75M$6.34M-0.9370CLNNClene3.2345 of 5 stars$4.24+17.1%$33.00+678.3%+4.8%$36.17M$340K-1.13100Analyst ForecastHigh Trading VolumeMRSNMersana Therapeutics4.2157 of 5 stars$7.38+3.1%$56.60+666.9%-80.1%$35.73M$34.77M-0.50150SCYXSCYNEXIS1.1457 of 5 stars$0.80-4.5%N/A-50.8%$35.21M$3.75M-2.0160News CoverageAnalyst RevisionRNXTRenovoRx2.893 of 5 stars$0.94-1.6%$7.25+671.3%-6.9%$34.94M$40K-2.476News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionALXOALX Oncology3.192 of 5 stars$0.97+50.7%$3.30+239.9%-51.0%$34.50MN/A-0.4440Analyst RevisionHigh Trading VolumeOKUROnKure Therapeutics3.2005 of 5 stars$2.80+10.7%$32.33+1,054.8%N/A$34.18MN/A-0.58N/ANews CoverageESLAEstrella Immunopharma2.2589 of 5 stars$0.92+1.0%$16.00+1,640.1%-26.8%$33.73MN/A-3.54N/ACLSDClearside Biomedical1.8565 of 5 stars$0.43+0.7%$4.20+886.1%-60.1%$33.21M$4.17M-1.1530Gap UpBTAIBioXcel Therapeutics4.5671 of 5 stars$5.67+3.5%$39.75+601.1%-54.2%$33.19M$2.27M-0.4590Short Interest ↓ Related Companies and Tools Related Companies XLO Alternatives CLNN Alternatives MRSN Alternatives SCYX Alternatives RNXT Alternatives ALXO Alternatives OKUR Alternatives ESLA Alternatives CLSD Alternatives BTAI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access